| Bioactivity | SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM[1]. |
| Target | IC50: 15.06 μM (SARS-CoV-2 PLpro) |
| CAS | 3053753-61-7 |
| Formula | C18H19N5O |
| Molar Mass | 321.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sousa BKP, et al., Discovery of Non-Covalent Inhibitors for SARS-CoV-2 PLpro: Integrating Virtual Screening, Synthesis, and Experimental Validation. ACS Med Chem Lett. 2024 Dec 2;15(12):2140-2149. |
SARS-CoV-2 PLpro-IN-1
CAS: 3053753-61-7 F: C18H19N5O W: 321.38
SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.0
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.